Blockade of central cyclooxygenase (COX) pathways enhances the cannabinoid-induced antinociceptive effects on inflammatory temporomandibular joint (TMJ) nociception
Authors:
- Dong K. AhnDong K. Ahn
- Hyo S. ChoiHCHyo S. Choi
- 1 November 2007
- journal article
- Published by Wolters Kluwer Health in Pain
- Vol. 132 (1) , 23-32
Abstract
The present study is the first to investigate the participation of central cyclooxygenase (COX) pathways in modulating the antinociceptive effects of intracisternally administered cannabinoid on nociception induced by inflammation of the temporomandibular joint (TMJ) in freely moving rats. Following intra-articular injection of 5% formalin in the TMJ, nociceptive scratching behavior was recorded for nine successive 5-min intervals in Sprague-Dawley rats. Intracisternal injection of 30 microg of WIN 55,212-2, a synthetic non-subtype-selective CB1/2 agonist, administered 20 min prior to formalin injection significantly reduced the number of scratches and duration of scratching induced by formalin compared with the vehicle-treated group. Antinociceptive effect of WIN 55,212-2 was blocked by intracisternal injection of 10 microg of AM251, a CB1 receptor-selective antagonist, but not by AM630, a CB2 receptor-selective antagonist. A 10 microg dose of WIN 55,212-2 that was ineffective in producing antinociception became effective following intracisternal administration of NS-398, a selective COX-2 inhibitor; indomethacin, a non-selective COX 1/2 inhibitor; acetaminophen, a putative COX-3 inhibitor, but not following pretreatment with the selective COX-1 inhibitor, SC-560. The ED(50) value of WIN 55,212-2 in the NS-398-treated group was significantly lower than that in the vehicle-treated group. Importantly, administration of low doses of COX inhibitors alone did not attenuate nociception. These results indicate that inhibition of central COX pathways, presumably via COX-2 inhibition, reduces inflammatory pain by enhancing the cannabinoid-induced antinociceptive effect. Based on our observations, combined administration of cannabinoids with COX inhibitors may hold a therapeutic promise in the treatment of inflammatory TMJ pain.Keywords
This publication has 51 references indexed in Scilit:
- Central cyclooxygenase inhibitors reduced IL-1β-induced hyperalgesia in temporomandibular joint of freely moving ratsPain, 2005
- COX-3 and the mechanism of action of paracetamol/acetaminophenProstaglandins, Leukotrienes and Essential Fatty Acids, 2005
- Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naïve rats and in rat models of inflammatory and neuropathic painEuropean Journal of Neuroscience, 2004
- Effect of antisense knock-down of α2a- and α2c-adrenoceptors on the antinociceptive action of clonidine on trigeminal nociception in the ratPain, 2002
- CB2 cannabinoid receptor-mediated peripheral antinociceptionPain, 2001
- Activation of spinal cannabinoid 1 receptors inhibits C‐fibre driven hyperexcitable neuronal responses and increases [35S]GTPγS binding in the dorsal horn of the spinal cord of noninflamed and inflamed ratsEuropean Journal of Neuroscience, 2000
- Molecular characterization of a peripheral receptor for cannabinoidsNature, 1993
- Structure of a cannabinoid receptor and functional expression of the cloned cDNANature, 1990
- Application of the formalin test to the study of orofacial pain in the ratNeuroscience Letters, 1989
- Selective and Potent Analgetics Derived from CannabinoidsThe Journal of Clinical Pharmacology, 1981